MedMira Inc. (TSX Venture: MIR, NSDQ: MMIRF),
a Canadian company, received a China patent for its rapid diagnostic device and
assay (Chinese Patent Application No. 02819646.5). The patents covers the rapid
flow-through technology (RFT) platform on which the company has built its line
of 3-minute tests for HIV, hepatitis and other diseases.
Previously,
MedMira was granted patents for the technology in the US and Europe. With the
third approval in hand, MedMira said it has won the “triple crown.”
In
the first nine months of fiscal 2008, MedMira reported revenues of $1.3 million,
which were lower than the $1.7 million the company recorded in the similar 2007
period.
MedMira says it is continuing to seek partners to further its
growth as a company. These initiatives include seeking companies who want to
build new rapid tests on MedMira’s RFT platform.
MedMira is an approved
supplier to US Agency for International Development (USAID) and the Pan American
Health Organization (PAHO).
